Rheumatology

Article	Citations
Activation of circulating monocytes by low-density lipoprotein—a risk factor for osteoarthritis?	122
Comment on: AI am a rheumatologist: a practical primer to large language models for rheumatologists: reply	89
Boxer’s shape, an unusual finding in nailfold capillaroscopy	83
Giant cell arteritis of the prostate	67
Clinical and serological resolution of pembrolizumab associated Sjögren’s syndrome: long-term follow-up	63
Will we ever agree on using low-dose glucocorticoids in treating rheumatoid arthritis?	63
Editor’s Acknowledgement	60
Comment on: ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies	57
Bullous periorbital oedema in anti-p155/140-positive dermatomyositis: a case series	56
Comment on: Increased risk of osteoporosis and femoral neck fractures in patients with familial Mediterranean fever—a large retrospective cohort study	53
Genetics of longitudinal kidney function in children and adults with systemic lupus erythematosus	51
Comment on: Persistence of circulating T-follicular helper cells after rituximab is associated with relapse of IgG4-related disease	50
Comment on: Switching from prednisolone to dexamethasone in difficult-to-treat rheumatoid arthritis	49
Comparative risk of blindness and vision-threatening ocular comorbidities in patients with Behçet’s disease versus the general population	48
COVID-19 vaccine affects neither prothrombotic antibody profile nor thrombosis in primary anti-phospholipid syndrome: a prospective study	47
Comment on: Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis—caution is key in interpreting retrospective data: Reply	47
Corrigendum to: Patient and Rheumatologist Perspectives on Tapering DMARDs in Rheumatoid Arthritis: A Qualitative Study	47
Haematologic malignancy-associated mucocutaneous paraneoplastic syndrome	47
The influence of biological DMARDs on aseptic arthroplasty loosening: a retrospective cohort study	45
Comment on: Muscle involvement in systemic lupus erythematosus: multimodal ultrasound assessment and relationship with physical performance	44
The role of IL-23 in joint disease	43
A case of carpal tunnel syndrome caused by gouty tophi confirmed by dual-source CT	42
Prosthetic infections following tocilizumab treatment in patients with rheumatoid arthritis	42
Granulomatosis with polyangiitis presenting as obstructive uropathy and vasculitic myopathy	41
Comment on: The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis: reply	41

Annular erythematous plaques as manifestation of vasculitis in pediatric Sjögren’s syndrome	41
Validation of a questionnaire for central nervous system aspects of joint pain: the CAP questionnaire	40
Biopsy vs imaging for the diagnosis of giant cell arteritis. Viewpoint 2: in favour of biopsy	40
Correction to: Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis	40
Clinical assessment of cardiac impairment favored by two-dimensional speckle tracking echocardiology in patients with systemic sclerosis	38
Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study	38
An ultrasound negative for subclinical synovitis in arthralgia patients: is it helpful in identifying those not developing arthritis?	38
Clinico–pathological phenotypes of systemic sclerosis–associated myopathy: analysis of a large multicentre cohort	38
VEXAS syndrome mimicking lupus-like disease	37
Bezoar secondary to NSAID use in a patient with inflammatory arthritis	37
Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients	36
Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study	36
Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs	35
Relapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study	35
Transient osteoporosis of the hip: a novel vascular manifestation of COVID-19?	35
Prodromal symptoms of rheumatoid arthritis in a primary care database: variation by ethnicity and socioeconomic status	35
Central retinal vein and cilioretinal artery occlusion in a case of systemic sclerosis treated with a JAK inhibitor figlotinib	34
A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis	34
Combined radiographic and US evaluations to decipher joint involvement in the hands of patients with SSc	34
Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3	34
The usefulness of ultrasound in predicting outcomes in patients with shoulder pain: a prospective observational study	33
Factors associated with delay in the diagnosis and treatment of systemic lupus erythematosus in adult patients: a systematic review	33
Identification of circulating microRNA patterns in patients in psoriasis and psoriatic arthritis	33
Comparison of salivary gland MRI and ultrasonography findings among patients with Sjögren’s syndrome over a wide age range	33
Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment	33
Gastrointestinal manifestations in systemic lupus erythematosus: data from an Indian multi-institutional inception (INSPIRE) cohort	32
The effect of silver fibre gloves on Raynaud’s phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial	32
Plasma proteomics for risk prediction and identification of novel drug targets in systemic lupus erythematosus	32
Tocilizumab-induced organizing pneumonia in a patient with systemic sclerosis–associated interstitial lung disease	32
IGFBP5 regulates fibrocartilage differentiation and cartilage injury induced by T-2 toxin via blocking IGF-1/IGF-1R signalling	32
Negative back beliefs are associated with increased odds of low back pain and disability: a 10-year cohort study in men	32
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE	31
Advances in the diagnosis of myocarditis in idiopathic inflammatory myopathies: an overview of diagnostic tests	31
Anti-nuclear valosin-containing protein-like autoantibody is associated with calcinosis and higher risk of cancer in systemic sclerosis	30
Effects of interleukin-6 signal inhibition on Treg subpopulations and association of Tregs with clinical outcomes in rheumatoid arthritis	30
The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis	30
Anti-SARS-CoV-2 vaccination in adolescent and adult patients with juvenile-onset systemic lupus erythematosus: tolerability and impact on disease activity	30
The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus	30
Lymphocyte subset phenotyping for the prediction of progression to inflammatory arthritis in anti-citrullinated-peptide antibody-positive at-risk individuals	29
The top 10 research priorities in psoriatic arthritis: a James Lind Alliance Priority Setting Partnership	29
P077 Developing a better explanation of osteoarthritis: results from a conjoint analysis of patient preferences	29
Identifying trajectories of radiographic spinal disease in ankylosing spondylitis: a 15-year follow-up study of the PSOAS cohort	29
Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE	29
Examination of nailfold videocapillaroscopy findings in ANCA-associated vasculitis	29
Corrigendum to: Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from EUROAPS registry	29
P004 Empowering the reproductive choices of patients with rheumatic disease: using the BSR 2022 pregnancy guidelines audit tool to evaluate pre-conception medication advice	29
P033 The intriguing association between fibromyalgia, hypermobility and neurodivergence: a pilot study	28
P107 Long-term efficacy of baricitinib in patients with rheumatoid arthritis with inadequate response to bDMARDs: results from RA-BEYOND up to 6.9-years of treatment	28
E051 Audit of the management of patients over 75 with osteoporotic fragility fractures in primary care	28
P058 Pneumocystis Jirovecii Infection in autoimmune inflammatory rheumatic diseases in Oxford	28

P041 Successful reversal of microvascular damage with standard therapy in a case of dermatomyositis overlap syndrome	28
26 Kawasaki’s disease vs systemic juvenile idiopathic arthritis, a diagnostic dilemma	27
Type I interferon dysregulation drives distinct pathogenic pathways in early- and late-onset lupus nephritis	27
P032 Methotrexate and hepatic tolerance in Juvenile Idiopathic Arthritis	27
P043 Income-Related Health Inequality and Osteoarthritis Intervention Outcomes: a Cohort Study	27
OA22 Methotrexate drug monitoring and referral patterns to Hepatology - can we improve detection and monitoring of hepatoxicity with methotrexate use?	27
Lupus serology: off target but still relevant to the treat-to-target strategy in systemic lupus erythematosus	27
Enhancing Gout Diagnosis with Deep Learning in Dual-energy Computed Tomography: A Retrospective Analysis of Crystal and Artifact Differentiation	27
P110 Challenges of meeting NICE guidance for rheumatoid arthritis in the modern era: a service audit	27
E078 Inflammation modifies the effect of rheumatoid arthritis in overall mortality among females	27
OA04 COVID-19 admissions and mortality in patients with early inflammatory arthritis: results from a national cohort	27
E44 Differences of hematological abnormalities between COVID-19 infection and multisystemic inflammatory syndrome (MIS-C)	27
P031 Adherence with Methotrexate in Tunisian Juvenile Idiopathic Arthritis Patients	26
P042 Using a Genetic PROBability tool (G-PROB) to aid diagnosis of patients with inflammatory arthritis: results from the Norfolk Arthritis Register	26
29 Juvenile idiopathic arthritis and osteogenesis imperfecta: an exceptional association	26
Neither ultrasound synovitis nor clinical-ultrasound phenotypes of established rheumatoid arthritis predict response to targeted therapy	26
The state of data sharing in rheumatology: a systematic review of top journal practices	26
P011 Rituximab and COVID-19 vaccines; are they fit for purpose?	26
67 Double impact: hypophosphatemic rickets and vitamin D intoxication	25
E046 Lytic lesions; metastatic disease or gout?	25
P143 Frailty is associated with inflammation, impaired glucose metabolism and reduced bone mineral density after adjustment for fat mass index: a UK biobank study	25
P114 Medication adherence to b/tsDMARDS remains sub-optimal in refractory rheumatoid arthritis	25
OA44 Increasing access to rehabilitation for knee and hip osteoarthritis - ESCAPE-pain in leisure/community centres	25
P173 The positive utility of PSAID-12 score in remote monitoring and the impact of gender and treatment on patient reported outcomes in psoriatic arthritis	25
P131 Adult coeliac disease and bone mineral density at the femoral neck, total hip and lumbar spine: an age- and sex-matched case-control study	25
P083 Undergraduate rheumatology teaching in the UK: a survey of teachers	25
P025 Risk assessment of covid 19 in patients with Juvenile Idiopathic Arthritis	24
High levels of EPSTI1 enhance IFN-β-mediated HLA-A expression and chemokine secretion in myoblasts in dermatomyositis	24
P179 A feasibility randomised controlled trial of a fibromyalgia self-management programme in a community setting with a nested qualitative study	24
P038 Let’s look at coxitis features in enthesitis-related arthritis population	24
Avacopan may not independently reduce ANCA titres in ANCA-associated vasculitis: a retrospective analysis of 57 patients	24
P261 Early and accurate diagnosis of patients with axial spondyloarthritis using machine learning: a predictive analysis from electronic health records in the United Kingdom	24
P047 Musculoskeletal symptoms as first clinical presentation of juvenile-onset systemic lupus erythematosus: Experience from a military internal medicine department	24
P073 Functional investigation of Osteoarthritis-associated non-coding variants using CRISPR/Cas9-mediated perturbation of active enhancer regions	24
OA12 An update on the integrated safety analysis of filgotinib in patients with moderate to severe active rheumatoid arthritis over a median of 4.3 years	23
P193 Bimekizumab improves key symptoms, disease activity and function in patients across the full spectrum of axial spondyloarthritis up to week 24: results from two phase 3 studies	23
P104 The role of occupational therapy for the self-management of rheumatoid arthritis: a mixed methods systematic review	23
Human dermal fibroblast-derived exosomes induce macrophage activation in systemic sclerosis	23
P185 Patients' and clinicians' perspectives on the clinical utility of the Rheumatoid Arthritis Foot Disease Activity Index	23
P004 Temporal and regional variation in the initiation of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort study	23
Comment on: Impact of baseline proteinuria level on long-term outcomes in lupus nephritis	23
The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs	23
P174 Identifying patterns of fatigue across flares in patients with axial spondyloarthritis	23
Comment on: Associations between loneliness, disease activity, and disease impact in inflammatory arthritis: a nationwide cross-sectional study among more than 12 000 patients	23
P133 Experiences of people with digital ulcers through filmed interviews	23
54 Kawasaki disease: experience in a general paediatric department of the CHU de Annaba Algeria	23
The impact of statins on coronary atherosclerosis progression and long-term cardiovascular disease risk in rheumatoid arthritis	23
A systematic review of patient-reported outcome measures in patients with anti-neutrophil cytoplasmic antibody associated vasculitis	22
COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis	22
Correction to: Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region	22
Comment on: Predictors of lack of response to methotrexate in juvenile idiopathic arthritis–associated uveitis	22
Correction to: TLR8 aggravates skin inflammation and fibrosis by activating skin fibroblasts in systemic sclerosis	22
Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate	22
Identification and characteristics of patients with axial psoriatic arthritis: clinical, phenotypic and imaging associations	22
Sensorineural hearing loss in anti-Interleukin-1 treated cryopyrin-associated periodic syndromes patients: risk factors and real-life barriers—an observational study	22
History of tonsillectomy is associated with glandular inflammation in Sjögren’s disease	22
Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles	21
Tofacitinib as a possible treatment for arthritis in an APDS2 patient	21
Incidence and predictors of demyelinating disease in spondyloarthritis: data from a longitudinal cohort study	21
Addressing the unmet needs of transitional care in juvenile idiopathic arthritis	21
Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry	21
Correction to: Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study	21
Highlights from the plenary session: eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome	21
Is the relationship between deprivation and outcomes in rheumatoid arthritis mediated by body mass index? A longitudinal cohort study	21
Ex vivo cell-based assay for assessment of response to TNF inhibitors in patients with rheumatic diseases	21
Effective and safe treatment of anti-CD38 therapy in systemic lupus erythematosus–associated refractory cerebral vasculitis induces immune tolerance	21
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis	20
Antibody predictors of mortality and lung function trends in myositis spectrum interstitial lung disease	20
Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation	20
Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis	20
Sarcoid myopathy: an insidious diagnosis that can mimic inclusion body myositis	20
Ixekizumab-associated disseminated tinea corporis in a patient with psoriatic arthritis and plaque psoriasis	20
Assessing the role of climate and the environment as co-factors for vasculitis diseases	20
Interstitial lung disease in limited cutaneous systemic sclerosis patients: never let your guard down	20
Use of biologics to treat relapsing and/or refractory polyarteritis nodosa: data from a European collaborative study	20
Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study	20
A multivariable prediction model to identify anti-CCP positive people in those with non-specific musculoskeletal symptoms in primary care	20
Discordance in patient and physician global assessment in relapsing polychondritis	20
Increased risk of myocarditis and arrythmias in anti-Ku-positive scleroderma–myositis overlap patients: a case series	20
Corrigendum to: Measuring disease activity in psoriatic arthritis: PASDAS implementation in a tightly monitored cohort reveals residual disease burden	20

Registry based studies on pregnancy and rheumatic diseases: generating actionable evidence	20
It is about time: the first validated biomarker for early diagnosis of systemic juvenile idiopathic arthritis	20
Patient burden and joint inflammation during development of RA from arthralgia: is it similar in ACPA-positive and ACPA-negative disease?	20
Predicting treatment response to methotrexate: are we closer to solving the enigma?	20
When should we start screening for hydroxychloroquine retinopathy?	20
Osteophytes’ position in subjects with DISH and right-sided aorta: verification of the ‘aortic pulsation protective effect’ theory	20
HLA-C*06–defined endotype in psoriatic disease: an ever-widening landscape	20
Giant thymic cyst overclouding the diagnosis of fibrodysplasia ossificans progressiva: an inconvenient coincidence	20
Interplay between genetics and lifestyle on pain susceptibility in women with fibromyalgia: the al-Ándalus project	19
Comment on: Concordance between myositis autoantibodies and anti-nuclear antibody patterns in a real-world, Australian cohort	19
Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: a case-control study	19
Teledidactic peer-tutored musculoskeletal ultrasound training for medical students—the TELMUS study	19
Quantitative chest imaging and prediction of mortality in rheumatoid arthritis–associated interstitial lung disease	19
Urological cancer risk in patients with rheumatoid arthritis compared to matched controls: a nationwide cohort study	19
Avacopan in an ocular complication of ANCA-PR3 vasculitis without kidney involvement	19
Correction to: Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis	19
Does plasma exchange have a role in ANCA-associated vasculitis? Viewpoint 2: plasma exchange may be useful under some circumstances	19
Emerging targeted therapies in ANCA-associated vasculitis	19
Comment on: Comparing clinical features between males and females with VEXAS syndrome: data from literature analysis of patient reports	19
Erratum to: Parvovirus B19 induces cellular senescence in human dermal fibroblasts: putative role in systemic sclerosis-associated fibrosis	19
Integrating imaging and biomarker assessment to better define psoriatic arthritis and predict response to biologic therapy	19
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study	19
Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews	19
Comment on: Systemic lupus erythematosus patients have unique changes in serum metabolic profiles across age associated with cardiometabolic risk: reply	19
Evaluation of patient-based disease activity score (PDAS) in the Japanese rheumatoid arthritis patient registry (NinJa registry)	19
Raynaud’s phenomenon and digital ischaemia induced by ixekizumab	19
Comment on: The clinical and cost effectiveness of splints for thumb base osteoarthritis: a randomized controlled clinical trial	19
OA36 Bimekizumab in patients with psoriatic arthritis: achievement and maintenance of Psoriatic Arthritis Response Criteria responses through 3 years in a phase 2b open-label extension study	18
E71 Distribution of cells and extracellular matrix in the normal marginal synovium of the hip joint capsule during the postnatal period	18
P027 Infliximab in the treatment of cerebral tuberculosis paradoxical reactions with vasculitis	18
Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment	18
Use of primary health care and radiological imaging preceding a diagnosis of rheumatoid arthritis: a nationwide cohort study in Denmark	18
2-deoxy-2[18F]fluoro-D-glucose positron emission tomography–computed tomography in rheumatological diseases	18
P229 Integrated analysis of dermal blister fluid proteomics and skin biopsy transcriptomics gives new insight into pathogenesis of systemic sclerosis	18
P083 Primary Goujerot- Sjögren Syndrome: a pediatric case report	18
20 Does hip involvement affect foot and ankle in juvenile idiopathic arthritis?	18
OA06 Single-centre experience of the use of Rituximab for inflammatory arthritis during the COVID-19 pandemic	18
P208 PET-CT scanning of GCA patients: the additive role of opportunistic screening for cardiovascular disease in a high-risk population	18
P110 Characteristics of Difficult to treat Rheumatoid Arthritis patients in a large District Hospital in the UK	18
Cancer risk with tocilizumab/sarilumab, abatacept and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study	18
Experience with upadacitinib in refractory polyarticular juvenile idiopathic arthritis	18
Defining the minimal important change (MIC) and meaningful change value (MCV) for the Psoriatic Arthritis Disease Activity Score (PASDAS) in a routine practice cohort of patients with psoriatic arthri	18
P046 The influence of deprivation in the outcomes of Psoriatic Arthritis within the UK - utilising Outcomes of Treatment in Psoriatic Arthritis Study Syndicate data	18
Nailfold videocapillaroscopy findings correlate with lung outcomes in idiopathic inflammatory myopathies–related interstitial lung disease	18
P212 Understandings and responses to joint pain: preliminary findings from a rapid ethnographic assessment in Northern Tanzania	18
P284 Evaluation of a self-management smartphone app for those living with Sjögren’s syndrome: a fully remote randomised pilot and feasibility trial	18
E005 Investigation into the post-diagnostic care and follow-up of patients with giant cell arteritis post-initiation of long-term glucocorticoids at University Hospitals Leicester NHS Foundation Trust	18
E68 Kawasaki Disease before and during COVID-19	18
P133 Attitudes to Technology supported Rheumatoid Arthritis care: Opportunities & Barriers for technology in RA - Key themes from Qualitative arm of Mixed-Methods Study	18
Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial spondyloarthritis	18
Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders	18
OA01 Cluster medicine: the role of genetics for identifying shared biological pathways between rheumatoid arthritis and common comorbidities for targeting treatments	18
P038 The importance of looking carefully for the cause(s)	18
Multicentric Castleman disease presenting with frequent urination	18
64 Conical teeth? Think outside the box!	18
P066 Systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patients	17
P123 Biologic dose tapering: a patient perspective	17
OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications	17
56 Prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy	17
P303 Development of a Behçet’s disease specific patient concerns inventory	17
P245 Identifying predictors of short-term response to rituximab in extra-glandular primary Sjogren’s Syndrome	17
E005 An audit of demographics, symptoms & investigations: Part of the survey of GCA in the SEHSCT during the COVID-19 pandemic	17
Physical activity in relation to the risk of systemic lupus erythematosus: a prospective study including 401 745 individuals	17
P081 Is it necessary to test vitamin D prior to zoledronate or denosumab treatment?	17
P139 Impact of hand function impairment on daily life of patients with systemic sclerosis - a qualitative study	17
P130 Pharmacist-led osteoporosis telephone service	17
61 The nailfold videocapillaroscopy in pediatric Behçet’s disease: a multi-center study	17
P055 Gabapentinoid use and the risk of fractures in patients with inflammatory arthritis: nested case-control study in the Clinical Practice Research Datalink Aurum	17
P163 The cytokine horror: Kawasaki disease shock syndrome complicated with macrophage activation syndrome	17
Step-down treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis: a real-life single-centre study	17
P094 Experts in lived experience: CLUSTER Champions and their successful collaboration in JIA research	17
P113 Cellular profiling of synovial fluid in inflammatory arthritis highlights disease-specific cell states with biological and diagnostic relevance	17
Citrate in the management of gout, urate nephrolithiasis and kidney disease: an old therapy rediscovered?	17
P167 COVID-19 perniosis, a differential diagnosis to consider in adolescent patients presenting with chilblain-like lesions	17
E001 Pre-screen chest X-ray before starting methotrexate in autoimmune disease	17
P012 Pneumocystis jirovecii pneumonia in rheumatology patients - a single centre ten-year audit	17
OA28 VEXAS, a service evaluation in Rheumatology at Sheffield: “Seek, and ye shall find”	17
P117 Remote monitoring of rheumatoid arthritis using RAPID3 to support patient-initiated follow up	17
P247 Novel therapeutic peptides targeting CD206 modulate ATP-induced release of inflammatory and B cell activating factors in lupus macrophages	17
P127 A retrospective cohort study assessing outcomes and safety in patients receiving low dose vs high dose cyclophosphamide in myositis interstitial lung disease	17
P257 Are there regional variations in access to biological disease modifying anti-rheumatic drugs for the treatment of psoriatic arthritis in England?	16
Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis	16
The SUMO components in rheumatoid arthritis	16
Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis	16
77 Case series of juvenile scleroderma from Nigeria	16
E048 A review of published data on reported staffing ratios for rheumatology specialist physiotherapists in rheumatology departments	16
Correction to: Survival and associated comorbidities in inclusion body myositis	16
Immune thrombocytopenia with clinical significance in systemic lupus erythematosus: a retrospective cohort study of 90 patients	16
Ultrasound subclinical synovitis in anti-CCP-positive at-risk individuals with musculoskeletal symptoms: an important and predictable stage in the rheumatoid arthritis continuum	16
Where are we now in biologic drugs for myositis?	16
P039 Haemophagocytic lymphohistiocytosis secondary to invasive aspergillosis in a patient with undiagnosed SLE	16
P278 Baseline characteristics and treatment response to ixekizumab categorised by sex in radiographic and non-radiographic axial spondylarthritis patients through 52 weeks: data from three phase III,	16
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease	16
P274 The effect of ixekizumab versus adalimumab on individual components of the ACR composite score, with and without concomitant methotrexate or other conventional synthetic DMARDs, at 52 weeks in pa	16
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease	16